Evidence map›Paper›PMID 29883404›Full record

ReviewInternational journal of molecular sciences2018

The CD36-PPARγ Pathway in Metabolic Disorders.

Loïze Maréchal, Maximilien Laviolette, Amélie Rodrigue-Way, Baly Sow, Michèle Brochu, Véronique Caron, André Tremblay

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06881706 (Relationship Between Biochemical and Anthropometric Variables and CD36 Levels in Metabolic Syndrome Patients After Low Calorie Diet), which is not on this map. Cited by 94 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06881706 nacompletednot on this mapstarted 2019, after this paper: background citation

Relationship Between Biochemical and Anthropometric Variables and CD36 Levels in Metabolic Syndrome Patients After Low Calorie Diet

TypeinterventionalSponsorOrdu UniversityRan2019 to 2020Enrolled65ConditionsMetabolic Syndrome, Weight LossArmsmedical nutrition therapy
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Exploring Active Ingredients and Mechanisms ofMolecules (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Article
  9. CD36 and Its Role in Obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  10. Review
  11. Article
  12. A Somatic Mutation in HIF-2α Affects Glucose and Lipid Metabolism via CD36 and Ceramide.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Loïze MaréchalResearch Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. loize.marechal@umontreal.ca.
Maximilien LavioletteResearch Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. maximilien.laviolette-brassard@umontreal.ca.
Amélie Rodrigue-WayResearch Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. amelierway@aol.com.
Baly SowResearch Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. baly.sow@umontreal.ca.
Michèle BrochuDepartment of Physiology, Faculty of Medicine, University of Montreal, Montréal, QC H3T 1J4, Canada. michele.brochu@umontreal.ca.
Véronique CaronResearch Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. veronique.caron.4@gmail.com.
André TremblayResearch Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada. andre.tremblay.1@umontreal.ca.ORCID 0000-0003-1547-9846
Centre Hospitalier Universitaire Sainte-Justine · CAUniversité de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uncovering the biological role of nuclear receptor peroxisome proliferator-activated receptors (PPARs) has greatly advanced our knowledge of the transcriptional control of glucose and energy metabolism. As such, pharmacological activation of PPARγ has emerged as an efficient approach for treating metabolic disorders with the current use of thiazolidinediones to improve insulin resistance in diabetic patients. The recent identification of growth hormone releasing peptides (GHRP) as potent inducers of PPARγ through activation of the scavenger receptor CD36 has defined a novel alternative to regulate essential aspects of lipid and energy metabolism. Recent advances on the emerging role of CD36 and GHRP hexarelin in regulating PPARγ downstream actions with benefits on atherosclerosis, hepatic cholesterol biosynthesis and fat mitochondrial biogenesis are summarized here. The response of PPARγ coactivator PGC-1 is also discussed in these effects. The identification of the GHRP-CD36-PPARγ pathway in controlling various tissue metabolic functions provides an interesting option for metabolic disorders.

Indexed as

Signal TransductionAnimalsCD36 AntigensDrug DiscoveryEnergy MetabolismFatty AcidsHumansInsulin ResistanceMetabolic DiseasesOligopeptidesPPAR gammaCD36 AntigensFatty AcidshexarelinOligopeptidesPPAR gammaatherosclerosisenergy metabolismfatty acid oxidationGHRPhexarelininsulin resistancePGC-1PPAR nuclear receptorsscavenger receptor

Identifiers

PMID29883404
PMCPMC5983591
OpenAlexW2803906210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.